New classification of ovarian, tube and peritoneal cancers. What has changed and what are the therapeutic consequences? [Neue klassifikation der ovarial-, tuben- und peritonealkarzinome. Was ändert sich und was sind die therapeutischen konsequenzen?]

被引:0
作者
Muallem M.Z. [1 ]
Rohr I. [1 ]
Braicu E. [1 ]
Sehouli J. [1 ]
机构
[1] Klinik für Gynäkologie, Charité - Universitätsmedizin Berlin, 13353 Berlin
来源
Der Onkologe | 2014年 / 20卷 / 7期
关键词
Fallopian tube cancer; New FIGO classification; Ovarian cancer; Peritoneal cancer; Tumor staging;
D O I
10.1007/s00761-014-2716-0
中图分类号
学科分类号
摘要
Background: The last FIGO classification was published in 1988. Due to new scientific knowledge and the improvement of diagnostic methods the new FIGO classification should provide a standard terminology which allows the comparison between patients from different centers. Furthermore, the tumors can be classified into various prognostic groups. Methods: The process of the proposed changes of the FIGO staging of ovarian, tubal and peritoneal cancers started 3 years ago. The proposal was sent to all relevant gynecological oncology institutions and societies worldwide. Results: The new FIGO classification reflects the current understanding of ovarian, tubal and peritoneal cancers and has a close relationship to the prognosis of every tumor stage. Discussion: The new FIGO staging contains among other things a revision of the FIGO III stage where stage IIIA1 is based on the spread in the retroperitoneal lymph nodes without intraperitoneal dissemination. A significantly improved overall survival could be shown here. The inclusion of retroperitoneal lymph nodes must be assigned cytologically or histologically. Extension of the tumor to the omentum, spleen or liver (stage IIIC) should be distinguished from isolated lung parenchymal, spleen or liver metastases (stage IVB). Stage IC is divided into three substages, which refer to the timing of capsule rupture. © 2014 Springer-Verlag.
引用
收藏
页码:658 / 661
页数:3
相关论文
共 14 条
[1]  
Prat J., Staging classification for cancer of the ovary, fallopian tube and peritoneum, Int J Gynaecol Obstet, 124, pp. 1-5, (2014)
[2]  
Vergote I., De Brabanter J., Fyles A., Bertelsen K., Einhorn N., Sevelda P., Gore M.E., Kaern J., Verrelst H., Sjovall K., Timmerman D., Vandewalle J., Van Gramberen M., Trope C.G., Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma, Lancet, 357, 9251, pp. 176-182, (2001)
[3]  
Bakkum-Gamez J.N., Richardson D.L., Seamon L.G., Et al., Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer, Obstet Gynecol, 113, pp. 11-17, (2009)
[4]  
Seidman J.D., Yemelyanova A.V., Khedmati F., Et al., Prognostic factors for stage I ovarian carcinoma, Int J Gynecol Pathol, 29, pp. 1-7, (2010)
[5]  
Dembo A.J., Davy M., Stenwig A.E., Berle E.J., Bush R.S., Kjorstad K., Prognostic factors in patients with stage I epithelial ovarian cancer, Obstetrics and Gynecology, 75, 2, pp. 263-273, (1990)
[6]  
Ahmed F.Y., Wiltshaw E., A'Hern R.P., Nicol B., Shepherd J., Blake P., Fisher C., Gore M.E., Natural history and prognosis of untreated stage I epithelial ovarian carcinoma, Journal of Clinical Oncology, 14, 11, pp. 2968-2975, (1996)
[7]  
Chan J.K., Tian C., Monk B.J., Herzog T., Kapp D.S., Bell J., Young R.C., Prognostic factors for high-risk early-stage epithelial ovarian cancer: A Gynecologic Oncology Group study, Cancer, 112, 10, pp. 2202-2210, (2008)
[8]  
Obermair A., Fuller A., Lopez-Varela E., Et al., A new prognostic model for FIGO stage 1 epithelial ovarian cancer, Gynecol Oncol, 104, pp. 607-611, (2007)
[9]  
Onda T., Yoshikawa H., Yasugi T., Mishima M., Nakagawa S., Yamada M., Matsumoto K., Taketani Y., Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to stage I/II patients and superior survival to other stage III patients, Cancer, 83, 8, pp. 1555-1560, (1998)
[10]  
Kanazawa K., Suzuki T., Tokashiki M., The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: Impact of nodal metastasis on patient survival, Gynecologic Oncology, 73, 2, pp. 237-241, (1999)